reverse payment settlements

The ACCC’s draft determination is notable as the first occasion on which a pharmaceutical settlement and licence agreement has been considered in the authorisation context in Australia. The scepticism with which the ACCC approached the...

Read More →

Pay-for-delay pharmaceutical agreements have attracted scrutiny from regulators in the US and EU. With last year's repeal of the intellectual property exemption in the CCA, these agreements are at greater risk of Australian regulatory attention...

Read More →